← All countries · Europe
46%
MCV1
2025 · WHO/UNICEF estimate
70%
DTP3
2025 · WHO/UNICEF estimate
70%
IPV complete
2025 · WHO/UNICEF estimate
74%
HepB3
2025 · WHO/UNICEF estimate
103
Measles cases
2025 reported
14
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 95%2025 · WHO/UNICEF estimate | 94.9% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 83%2025 · WHO/UNICEF estimate | 83.2% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 70%2025 · WHO/UNICEF estimate | 70.2% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 83%2025 · WHO/UNICEF estimate | 83.2% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 70%2025 · WHO/UNICEF estimate | 70.3% | C · weak | |
| MCV1First dose of measles-containing vaccine | 46%2025 · WHO/UNICEF estimate | 45.5% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 54%2025 · WHO/UNICEF estimate | 54.5% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 46%2025 · WHO/UNICEF estimate | 45.5% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 74%2025 · WHO/UNICEF estimate | 73.7% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 95%2025 · WHO/UNICEF estimate | — | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 70%2025 · WHO/UNICEF estimate | 70.2% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 0%2012 · Administrative (country-reported) | 0% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 0%2012 · Administrative (country-reported) | 0% | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | 0%2012 · Administrative (country-reported) | 0% | too few points | D · poor |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2012 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2012 · Administrative (country-reported) | 0% | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 0%2012 · Administrative (country-reported) | 0% | too few points | D · poor |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 4%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 4%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 2%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 1032025 | 32.8per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 12025 | 0.3per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 282025 | 8.9per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 142025 | 4.5per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (31 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | children aged 0-5 years |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | M2 | General/routine | children from 2 months to 5 years of age |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M3-M4 | General/routine | children from 2 months to 5 years of age |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M4-M6 | General/routine | children from 2 months to 5 years of age |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 4 | M18-Y2 | General/routine | children from 2 months to 5 years of age |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y5-Y7 | General/routine | children from 5 years old to 13 years old |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Travellers | Travellers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Clinical indications (hemodialysis patients, hemophilia, sexual partners of HBsAg positive persons, tissue and organ transplantation,, health and care workers, risik groups (for exemple: injecting drug users,persons serving a prison sentence, beauticians, tatoo artist..) | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Clinical indications (hemodialysis patients, hemophilia, sexual partners of HBsAg positive persons, tissue and organ transplantation,, health and care workers, risik groups (for exemple: injecting drug users,persons serving a prison sentence, beauticians, tatoo artist..) | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | children aged 0-15 years |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M1 | General/routine | children aged 0-15 years |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | General/routine | children aged 0-15 years |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Clinical indications (anatomical or functional asplenia) | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y9-Y14 | HPV administered to females and males | girls and boys aged 13-18 years |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | Y9-Y14 | HPV administered to females and males | girls and boys aged 13-18 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | Travellers, clinical indications ( sickle cell disease, anatomical or functional asplenia) | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Travellers | Travellers, clinical indications ( sickle cell disease, anatomical or functional asplenia) | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y1 | General/routine | children from 12 months to 14 years of age |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Travellers | Travellers | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y6 | General/routine | children from 12 months to 14 years of age |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Risk group(s) | Clinical indications (anatomical or functional asplenia, sickle cell anemia, organ transplantation, congenital or acquired immunodeficiency, invasive pneumococcal disease, cerebrospinal fluid, cochlear implant, nephrotic syndrome or renal failure, cystic fibrosis in children, primary ciliary dyskinesia in children, bronchopulmonary dysplasia in children, chronic obstructive diseases in children) | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | Clinical indications (anatomical or functional asplenia, sickle cell anemia, organ transplantation, congenital or acquired immunodeficiency, invasive pneumococcal disease, cerebrospinal fluid, cochlear implant, nephrotic syndrome or renal failure, cystic fibrosis in children, primary ciliary dyskinesia in children, bronchopulmonary dysplasia in children, chronic obstructive diseases in children) | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | Risk group(s) | Infants | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y14-Y18 | General/routine | children/youth from 7-18 years of age |
| TTTT (Tetanus toxoid) vaccine | 1 | Risk group(s) | Travelers, clinical indications ( after the injury, if not fully vaccinated against tetanus) | |
| TTTT (Tetanus toxoid) vaccine | 1 | Travellers | Travelers, clinical indications ( after the injury, if not fully vaccinated against tetanus) | |
| VARICELLAVaricella vaccine | 1 | Risk group(s) | Children and adults without previous infection |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.